Novel and emerging treatments for autism spectrum disorders: A systematic review

Annals of Clinical Psychiatry

Volumn 21, Issue 4, 2009, Pages 213-236

  Rossignol, Daniel A ^a  

^a International Child Development Resource Center   (United States)

Author keywords

Autism; Diets; Novel treatments; Supplements

Indexed keywords

ANTIOXIDANT; CHOLINESTERASE INHIBITOR; MELATONIN; NALTREXONE;

AUTISM; CHILD; DIET SUPPLEMENTATION; DIET THERAPY; HUMAN; MUSIC THERAPY; OFF LABEL DRUG USE; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANTIOXIDANTS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; CHOLINESTERASE INHIBITORS; DIETARY SUPPLEMENTS; HUMANS; MELATONIN; MUSIC THERAPY; NALTREXONE; OFF-LABEL USE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 75649107225     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: None     Document Type: Review

References (321)

1. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
2. Baird G, Charman T, Baron-Cohen S, et al. A screening instrument for autism at 18 months of age: a 6-year follow-up study. J Am Acad Child Adolesc Psychiatry. 2000;39:694-702. (Pubitemid 30351219)
3. Bertrand J, Mars A, Boyle C, et al. Prevalence of autism in a United States population: the Brick Township, New Jersey, investigation. Pediatrics. 2001;108:1155-1161. (Pubitemid 33021192)
4. Chakrabarti S, Fombonne E. Pervasive developmental disorders in preschool children. JAMA. 2001;285:3093-3099. (Pubitemid 32578206)
5. Rice C. Prevalence of autism spectrum disorders - autism and developmental disabilities monitoring network, 14 sites, United States, 2002. MMWR. 2007;56:12-28.
6. Muhle R, Trentacoste SV, Rapin I. The genetics of autism. Pediatrics. 2004;113:e472-e486.
7. Green VA, Pituch KA, Itchon J, et al. Internet survey of treatments used by parents of children with autism. Res Dev Disabil. 2006;27:70-84. (Pubitemid 41785473)
8. Aman MG, Lam KS, Collier-Crespin A. Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio. J Autism Dev Disord. 2003;33:527-534. (Pubitemid 37351601)
9. Witwer A, Lecavalier L. Treatment incidence and patterns in children and adolescents with autism spectrum disorders. J Child Adolesc Psychopharmacol. 2005;15:671-681. (Pubitemid 41434371)
10. Langworthy-Lam KS, Aman MG, Van Bourgondien ME. Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina. J Child Adolesc Psychopharmacol. 2002;12:311-321. (Pubitemid 36169283)
11. US Food and Drug Administration. FDA approves the first drug to treat irritability associated with autism, risperdal 2006. Available at: http://www.fda.gov/bbs/topics/news/2006/new01485.html. Accessed May 6, 2009.
12. Scott LJ, Dhillon S. Risperidone: a review of its use in the treatment of irritability associated with autistic disorder in children and adolescents. Paediatr Drugs. 2007;9:343-354. (Pubitemid 47557115)
13. Rosebush PI, Mazurek MF. Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology. 1999;52:782-785. (Pubitemid 29120185)
14. Hyman SL, Levy SE. Introduction: novel therapies in developmental disabilities - hope, reason, and evidence. Ment Retard Dev Disabil Res Rev. 2005;11:107-109. (Pubitemid 40981691)
15. American Academy of Pediatrics. Counseling families who choose complementary and alternative medicine for their child with chronic illness or disability. Committee on Children With Disabilities. Pediatrics. 2001;107:598-601.
16. Phillips B, Ball C, Sackett D, et al. Oxford Centre for Evidence-based Medicine Levels of Evidence. 2001. Available at: http://www.cebm.net/levels-of- evidence.asp. Accessed May 6, 2009.
17. Sandler AD, Bodfish JW. Placebo effects in autism: lessons from secretin. J Dev Behav Pediatr. 2000;21:347-350.
18. King BH, Wright DM, Handen BL, et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2001;40:658-665. (Pubitemid 32473379)
19. Defining and describing complementary and alternative medicine. Panel on Definition and Description, CAM Research Methodology Conference, April 1995. Altern Ther Health Med. 1997;3:49-57.
20. Loman DG. The use of complementary and alternative health care practices among children. J Pediatr Health Care. 2003;17:58-63. (Pubitemid 36890662)
21. Sanders H, Davis MF, Duncan B, et al. Use of complementary and alternative medical therapies among children with special health care needs in southern Arizona. Pediatrics. 2003;111:584-587. (Pubitemid 36330716)
22. Wong HH, Smith RG. Patterns of complementary and alternative medical therapy use in children diagnosed with autism spectrum disorders. J Autism Dev Disord. 2006;36:901-909. (Pubitemid 44440109)
23. Hanson E, Kalish LA, Bunce E, et al. Use of complementary and alternative medicine among children diagnosed with autism spectrum disorder. J Autism Dev Disord. 2007;37:628-636. (Pubitemid 46571719)
24. Wong VC. Use of complementary and alternative medicine (CAM) in autism spectrum disorder (ASD): comparison of Chinese and Western culture (part A). J Autism Dev Disord. 2009;39:454-463.
25. Autism Research Institute. Parent ratings of behavorial effects of biomedical interventions. ARI Publ 34; February 2008. http://www.autism.com/ treatable/form34qr.htm. Accessed May 6, 2009.
26. Levy SE, Mandell DS, Merhar S, et al. Use of complementary and alternative medicine among children recently diagnosed with autistic spectrum disorder. J Dev Behav Pediatr. 2003;24:418-423. (Pubitemid 38035610)
27. Golnik AE, Ireland M. Complementary alternative medicine for children with autism: a physician survey. J Autism Dev Disord. 2009;39:996-1005.
28. Liptak GS, Orlando M, Yingling JT, et al. Satisfaction with primary health care received by families of children with developmental disabilities. J Pediatr Health Care. 2006;20:245-252. (Pubitemid 44007080)
29. Kemper KJ, O'Connor KG. Pediatricians' recommendations for complementary and alternative medical (CAM) therapies. Ambul Pediatr. 2004;4:482-487. (Pubitemid 39600039)
30. Myers SM, Johnson CP. Management of children with autism spectrum disorders. Pediatrics. 2007;120:1162-1182. (Pubitemid 350085560)
31. Muskiet FA, Kemperman RF. Folate and long-chain polyunsaturated fatty acids in psychiatric disease. J Nutr Biochem. 2006;17:717-727. (Pubitemid 44557052)
32. Fernstrom JD. Can nutrient supplements modify brain function? Am J Clin Nutr. 2000;71:1669S-1675S. (Pubitemid 30396262)
33. Lakhan SE, Vieira KF. Nutritional therapies for mental health disorders. Nutr J. 2008;7:2.
34. Carlton RM, Ente G, Blum L, et al. Rational dosages of nutrients have a prolonged effect on learning disabilities. Altern Ther Health Med. 2000;6:85-91. (Pubitemid 30441326)
35. Benton D, Roberts G. Effect of vitamin and mineral supplementation on intelligence of a sample of schoolchildren. Lancet. 1988;1:140-143. (Pubitemid 18027994)
36. Osendarp SJ, Baghurst KI, Bryan J, et al. Effect of a 12-mo micronutrient intervention on learning and memory in well-nourished and marginally nourished school-aged children: 2 parallel, randomized, placebo-controlled studies in Australia and Indonesia. Am J Clin Nutr. 2007;86:1082-1093. (Pubitemid 47538312)
37. Haskell CF, Scholey AB, Jackson PA, et al. Cognitive and mood effects in healthy children during 12 weeks' supplementation with multi-vitamin/minerals. Br J Nutr. 2008;100:1086-1096.
38. MacLellan D, Taylor J, Wood K. Food intake and academic performance among adolescents. Can J Diet Pract Res. 2008;69:141-144.
39. Schreck KA, Williams K, Smith AF. A comparison of eating behaviors between children with and without autism. J Autism Dev Disord. 2004;34:433-438. (Pubitemid 39127718)
40. Herndon AC, DiGuiseppi C, Johnson SL, et al. Does nutritional intake differ between children with autism spectrum disorders and children with typical development? J Autism Dev Disord. 2009;39:212-222.
41. Ng F, Berk M, Dean O, et al. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol. 2008;11:851-876.
42. Tsaluchidu S, Cocchi M, Tonello L, et al. Fatty acids and oxidative stress in psychiatric disorders. BMC Psychiatry. 2008;8(suppl 1):S5.
43. Yorbik O, Sayal A, Akay C, et al. Investigation of antioxidant enzymes in children with autistic disorder. Prostaglandins Leukot Essent Fatty Acids. 2002;67:341-343. (Pubitemid 35397373)
44. James SJ, Melnyk S, Jernigan S, et al. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am J Med Genet B Neuropsychiatr Genet. 2006;141:947-956. (Pubitemid 44905454)
45. James SJ, Cutler P, Melnyk S, et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr. 2004;80:1611-1617. (Pubitemid 41103861)
46. Chauhan A, Chauhan V, Brown WT, et al. Oxidative stress in autism: increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin - the antioxidant proteins. Life Sci. 2004;75:2539-2549. (Pubitemid 39195260)
47. Chauhan A, Chauhan V. Oxidative stress in autism. Pathophysiology. 2006;13:171-181.
48. Sperner-Unterweger B. Immunological aetiology of major psychiatric disorders: evidence and therapeutic implications. Drugs. 2005;65:1493-1520. (Pubitemid 41124305)
49. Pardo CA, Vargas DL, Zimmerman AW. Immunity, neuroglia and neuroinflammation in autism. Int Rev Psychiatry. 2005;17:485-495. (Pubitemid 43086675)
50. Vargas DL, Nascimbene C, Krishnan C, et al. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol. 2005;57:67-81. (Pubitemid 40053317)
51. Chez MG, Dowling T, Patel PB, et al. Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children. Pediatr Neurol. 2007;36:361-365. (Pubitemid 46873913)
52. Connolly AM, Chez MG, Pestronk A, et al. Serum autoantibodies to brain in Landau-Kleffner variant, autism, and other neurologic disorders. J Pediatr. 1999;134:607-613. (Pubitemid 30180601)
53. Connolly AM, Chez M, Streif EM, et al. Brain-derived neurotrophic factor and autoantibodies to neural antigens in sera of children with autistic spectrum disorders, Landau-Kleffner syndrome, and epilepsy. Biol Psychiatry. 2006;59:354-363. (Pubitemid 43238361)
54. Torrente F, Ashwood P, Day R, et al. Small intestinal enteropathy with epithelial IgG and complement deposition in children with regressive autism. Mol Psychiatry. 2002;7:375-382, 334.
55. Furlano RI, Anthony A, Day R, et al. Colonic CD8 and gamma delta T-cell infiltration with epithelial damage in children with autism. J Pediatr. 2001;138:366-372. (Pubitemid 32207139)
56. Ashwood P, Anthony A, Pellicer AA, et al. Intestinal lymphocyte populations in children with regressive autism: evidence for extensive mucosal immunopathology. J Clin Immunol. 2003;23:504-517. (Pubitemid 38177671)
57. Balzola F, Daniela C, Repici A, et al. Autistic enterocolitis: confirmation of a new inflammatory bowel disease in an Italian cohort of patients. Gastroenterology. 2005;128:A303.
58. Horvath K, Papadimitriou JC, Rabsztyn A, et al. Gastrointestinal abnormalities in children with autistic disorder. J Pediatr. 1999;135:559-563. (Pubitemid 30180444)
59. Valicenti-McDermott M, McVicar K, Rapin I, et al. Frequency of gastrointestinal symptoms in children with autistic spectrum disorders and association with family history of autoimmune disease. J Dev Behav Pediatr. 2006;27:S128-S136. (Pubitemid 44620294)
60. Horvath K, Perman JA. Autism and gastrointestinal symptoms. Curr Gastroenterol Rep. 2002;4:251-258.
61. Finegold SM, Molitoris D, Song Y, et al. Gastrointestinal microflora studies in late-onset autism. Clin Infect Dis. 2002;35:S6-S16.
62. Song Y, Liu C, Finegold SM. Real-time PCR quantitation of clostridia in feces of autistic children. Appl Environ Microbiol. 2004;70:6459-6465. (Pubitemid 39518551)
63. Parracho HM, Bingham MO, Gibson GR, et al. Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children. J Med Microbiol. 2005;54:987-991. (Pubitemid 41395858)
64. Jyonouchi H, Geng L, Ruby A, et al. Evaluation of an association between gastrointestinal symptoms and cytokine production against common dietary proteins in children with autism spectrum disorders. J Pediatr. 2005;146:605-610. (Pubitemid 40616244)
65. Buie TM. Gastroesophageal reflux in children with autism: how do children present and can one test these children? J Pediatr Gastroenterol Nutr. 2005;41:505.
66. Levy SE, Hyman SL. Novel treatments for autistic spectrum disorders. Ment Retard Dev Disabil Res Rev. 2005;11:131-142. (Pubitemid 40981694)
67. Nir I, Meir D, Zilber N, et al. Brief report: circadian melatonin, thyroid-stimulating hormone, prolactin, and cortisol levels in serum of young adults with autism. J Autism Dev Disord. 1995;25:641-654. (Pubitemid 26006039)
68. Kulman G, Lissoni P, Rovelli F, et al. Evidence of pineal endocrine hypofunction in autistic children. Neuro Endocrinol Lett. 2000;21:31-34. (Pubitemid 30113676)
69. Tordjman S, Anderson GM, Pichard N, et al. Nocturnal excretion of 6-sulphatoxymelatonin in children and adolescents with autistic disorder. Biol Psychiatry. 2005;57:134-138. (Pubitemid 40094713)
70. Melke J, Goubran Botros H, Chaste P, et al. Abnormal melatonin synthesis in autism spectrum disorders. Mol Psychiatry. 2008;13:90-98. (Pubitemid 350275181)
71. Jan JE, O'Donnell ME. Use of melatonin in the treatment of paediatric sleep disorders. J Pineal Res. 1996;21:193-199. (Pubitemid 126733135)
72. Hayashi E. Effect of melatonin on sleep-wake rhythm: the sleep diary of an autistic male. Psychiatry Clin Neurosci. 2000;54:383-384. (Pubitemid 30431869)
73. Ishizaki A, Sugama M, Takeuchi N. [Usefulness of melatonin for developmental sleep and emotional/behavior disorders - studies of melatonin trial on 50 patients with developmental disorders] [In Japanese]. No To Hattatsu. 1999;31:428-437.
74. Paavonen EJ, Nieminen-von Wendt T, Vanhala R, et al. Effectiveness of melatonin in the treatment of sleep disturbances in children with Asperger disorder. J Child Adolesc Psychopharmacol. 2003;13:83-95. (Pubitemid 36570191)
75. Giannotti F, Cortesi F, Cerquiglini A, et al. An open-label study of controlled-release melatonin in treatment of sleep disorders in children with autism. J Autism Dev Disord. 2006;36:741-752. (Pubitemid 44284978)
76. Andersen IM, Kaczmarska J, McGrew SG, et al. Melatonin for insomnia in children with autism spectrum disorders. J Child Neurol. 2008;23:482-485. (Pubitemid 351566859)
77. Wasdell MB, Jan JE, Bomben MM, et al. A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. J Pineal Res. 2008;44:57-64. (Pubitemid 350231110)
78. Garstang J, Wallis M. Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child Care Health Dev. 2006;32:585-589. (Pubitemid 44210097)
79. Wirojanan J, Jacquemont S, Diaz R, et al. The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. J Clin Sleep Med. 2009;5:145-150.
80. Filipek PA, Juranek J, Nguyen MT, et al. Relative carnitine deficiency in autism. J Autism Dev Disord. 2004;34:615-623. (Pubitemid 40044667)
81. Ellaway CJ, Peat J, Williams K, et al. Medium-term open label trial of L-carnitine in Rett syndrome. Brain Dev. 2001;23 suppl 1:S85-S89.
82. Ellaway C, Williams K, Leonard H, et al. Rett syndrome: randomized controlled trial of L-carnitine. J Child Neurol. 1999;14:162-167. (Pubitemid 29146696)
83. Tani Y, Fernell E, Watanabe Y, et al. Decrease in 6R-5,6,7,8- tetrahydrobiopterin content in cerebrospinal fluid of autistic patients. Neurosci Lett. 1994;181:169-172.
84. Komori H, Matsuishi T, Yamada S, et al. Cerebrospinal fluid biopterin and biogenic amine metabolites during oral R-THBP therapy for infantile autism. J Autism Dev Disord. 1995;25:183-193.
85. Nagahata M, Kazamaturi H, Nuruse H, et al. Clinical evaluation of apropterin hydrochloride (R-THBP) on infantile autism: a multicenter cooperative study. In: Naruse H, Ornitz EM, eds. Neurobiology of infantile autism. Proceedings of the International Symposium on Neurobiology of Infantile Autism; Nov 10-11, 1990; Tokyo, Japan. Amsterdam: Elsevier Science Ltd; 1992: 351-354.
86. Fernell E, Watanabe Y, Adolfsson I, et al. Possible effects of tetrahydrobiopterin treatment in six children with autism-clinical and positron emission tomography data: a pilot study. Dev Med Child Neurol. 1997;39:313-318. (Pubitemid 27271708)
87. Danfors T, von Knorring AL, Hartvig P, et al. Tetrahydrobiopterin in the treatment of children with autistic disorder: a double-blind placebo-controlled crossover study. J Clin Psychopharmacol. 2005;25:485-489. (Pubitemid 41368374)
88. Nakane Y, Naruse H, Takesada M, et al. Clinical effect of R-THBP on infantile autism. In: Naruse H, Ornitz EM, eds. Neurobiology of infantile autism. Proceedings of the International Symposium on Neurobiology of Infantile Autism; Nov 10-11, 1990; Tokyo, Japan. Amsterdam: Elsevier Science Ltd; 1992: 337-350.
89. Monks G, Juracek L, Weigand D, et al. A case of scurvy in an autistic boy. J Drugs Dermatol. 2002;1:67-69.
90. Duggan CP, Westra SJ, Rosenberg AE. Case records of the Massachusetts General Hospital. Case 23-2007. A 9-year-old boy with bone pain, rash, and gingival hypertrophy. N Engl J Med. 2007;357:392-400.
91. Dolske MC, Spollen J, McKay S, et al. A preliminary trial of ascorbic acid as supplemental therapy for autism. Prog Neuropsychopharmacol Biol Psychiatry. 1993;17:765-774. (Pubitemid 23280951)
92. Chez MG, Buchanan CP, Aimonovitch MC, et al. Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders. J Child Neurol. 2002;17:833-837. (Pubitemid 36193075)
93. Adams JB, Holloway C. Pilot study of a moderate dose multivitamin/mineral supplement for children with autistic spectrum disorder. J Altern Complement Med. 2004;10:1033-1039. (Pubitemid 40180010)
94. Paczynski M. Piracetam: a novel therapy for autism? J Autism Dev Disord. 1997;27:628-630.
95. Akhondzadeh S, Tajdar H, Mohammadi MR, et al. A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder. Child Psychiatry Hum Dev. 2008;39:237-245. (Pubitemid 351839896)
96. Richardson AJ, Calvin CM, Clisby C, et al. Fatty acid deficiency signs predict the severity of reading and related difficulties in dyslexic children. Prostaglandins Leukot Essent Fatty Acids. 2000;63:69-74.
97. Richardson AJ. Omega-3 fatty acids in ADHD and related neurodevelopmental disorders. Int Rev Psychiatry. 2006;18:155-172. (Pubitemid 43791677)
98. Richardson AJ. Long-chain polyunsaturated fatty acids in childhood developmental and psychiatric disorders. Lipids. 2004;39:1215-1222.
99. Stevens LJ, Zentall SS, Abate ML, et al. Omega-3 fatty acids in boys with behavior, learning, and health problems. Physiol Behav. 1996;59:915-920. (Pubitemid 26110718)
100. Vancassel S, Durand G, Barthelemy C, et al. Plasma fatty acid levels in autistic children. Prostaglandins Leukot Essent Fatty Acids. 2001;65:1-7. (Pubitemid 32783435)
101. Bell JG, MacKinlay EE, Dick JR, et al. Essential fatty acids and phospholipase A2 in autistic spectrum disorders. Prostaglandins Leukot Essent Fatty Acids. 2004;71:201-204. (Pubitemid 39037633)
102. Sliwinski S, Croonenberghs J, Christophe A, et al. Polyunsaturated fatty acids: do they have a role in the pathophysiology of autism? Neuro Endocrinol Lett. 2006;27:465-471. (Pubitemid 46043603)
103. Schultz ST, Klonoff-Cohen HS, Wingard DL, et al. Breastfeeding, infant formula supplementation, and autistic disorder: the results of a parent survey. Int Breastfeed J. 2006;1:16.
104. Johnson SM, Hollander E. Evidence that eicosapentaenoic acid is effective in treating autism. J Clin Psychiatry. 2003;64:848-849. (Pubitemid 36897224)
105. Patrick L, Salik R. The effect of essential fatty acid supplementation on language development and learning skills in autism and Asperger's syndrome. Autism Asperger's Digest. 2005;Jan/Feb:36-37.
106. Politi P, Cena H, Comelli M, et al. Behavioral effects of omega-3 fatty acid supplementation in young adults with severe autism: an open label study. Arch Med Res. 2008;39:682-685.
107. Meguid NA, Atta HM, Gouda AS, et al. Role of polyunsaturated fatty acids in the management of Egyptian children with autism. Clin Biochem. 2008;41:1044-1048.
108. Amminger GP, Berger GE, Schafer MR, et al. Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. Biol Psychiatry. 2007;61:551-553. (Pubitemid 46185334)
109. Bent S, Bertoglio K, Hendren RL. Omega-3 fatty acids for autistic spectrum disorder: a systematic review. J Autism Dev Disord. 2009; 39:1145-1154.
110. Adams JB, George F, Audhya T. Abnormally high plasma levels of vitamin B6 in children with autism not taking supplements compared to controls not taking supplements. J Altern Complement Med. 2006;12:59-63. (Pubitemid 43346324)
111. Strambi M, Longini M, Hayek J, et al. Magnesium profile in autism. Biol Trace Elem Res. 2006;109:97-104. (Pubitemid 43162261)
112. Bonish VE. Experiences with vitamin B6 with brain-damaged children with autistic syndrome. Proxis der Kinderpsychologie. 1968;8:308-310.
113. Rimland B. An orthomolecular study of psychotic children. Orthomolecular Psychiatry. 1974;3:371-377.
114. Barthelemy C, Martineau J, Bruneau N, et al. [Clinical (behavior scale items), electrophysiologic (conditioned evoked potentials) and biochemical (urinary homovanillic acid) markers in infantile autism] [In French]. Encephale. 1985;11:101-106.
115. Lelord G, Callaway E, Muh JP, et al. [Modifications in urinary homovanillic acid after ingestion of vitamin B6; functional study in autistic children (author's transl)] [In French]. Rev Neurol (Paris). 1978;134:797-801.
116. Martineau J, Garreau B, Barthelemy C, et al. Effects of vitamin B6 on averaged evoked potentials in infantile autism. Biol Psychiatry. 1981;16:627-641. (Pubitemid 11043143)
117. Martineau J, Barthelemy C, Cheliakine C, et al. Brief report: an open middle-term study of combined vitamin B6-magnesium in a subgroup of autistic children selected on their sensitivity to this treatment. J Autism Dev Disord. 1988;18:435-447.
118. Martineau J, Barthelemy C, Roux S, et al. Electrophysiological effects of fenfluramine or combined vitamin B6 and magnesium on children with autistic behaviour. Dev Med Child Neurol. 1989;31:721-727. (Pubitemid 20021698)
119. Menage P, Thibault G, Barthelemy C, et al. CD 4+ CD 45 RA+ T lymphocyte deficiency in autistic children: effect of a pyridoxine-magnesium treatment. Brain Dysfunct. 1992;5:326-333. (Pubitemid 23145196)
120. Barthelemy C, Garreau B, Leddet I, et al. [Biological and clinical effects of oral magnesium and associated magnesium-vitamin B6 administration on certain disorders observed in infantile autism (author's transl)] [In French]. Therapie. 1980;35:627-632.
121. Barthelemy C, Garreau B, Leddet I. Behavioral and biological effects of oral magnesium, vitamin B6 and combined magnesium-vitamin B6 administration in autistic children. Magnes Bull. 1981;2:150-153.
122. Jonas C, Etienne T, Barthelemy C, et al. [Clinical and biochemical value of Magnesium + vitamin B6 combination in the treatment of residual autism in adults] [In French]. Therapie. 1984;39:661-669.
123. Martineau J, Barthelemy C, Garreau B, et al. Vitamin B6, magnesium, and combined B6-Mg: therapeutic effects in childhood autism. Biol Psychiatry. 1985;20:467-478. (Pubitemid 16033745)
124. Lelord G, Muh JP, Barthelemy C, et al. Effects of pyridoxine and magnesium on autistic symptoms - initial observations. J Autism Dev Disord. 1981;11:219-230. (Pubitemid 11052512)
125. Lelord G, Callaway E, Muh JP. Clinical and biological effects of high doses of vitamin B6 and magnesium on autistic children. Acta Vitaminol Enzymol. 1982;4:27-44. (Pubitemid 12063136)
126. Rimland B, Callaway E, Dreyfus P. The effect of high doses of vitamin B6 on autistic children: a double-blind crossover study. Am J Psychiatry. 1978;135:472-475. (Pubitemid 8309421)
127. Tolbert L, Haigler T, Waits MM, et al. Brief report: lack of response in an autistic population to a low dose clinical trial of pyridoxine plus magnesium. J Autism Dev Disord. 1993;23:193-199. (Pubitemid 23117570)
128. Findling RL, Maxwell K, Scotese-Wojtila L, et al. High-dose pyridoxine and magnesium administration in children with autistic disorder: an absence of salutary effects in a double-blind, placebo-controlled study. J Autism Dev Disord. 1997;27:467-478. (Pubitemid 27319213)
129. Kuriyama S, Kamiyama M, Watanabe M, et al. Pyridoxine treatment in a subgroup of children with pervasive developmental disorders. Dev Med Child Neurol. 2002;44:284-286. (Pubitemid 34406521)
130. Nye C, Brice A. Combined vitamin B6-magnesium treatment in autism spectrum disorder. Cochrane Database Syst Rev. 2005;(4):CD003497.
131. Mousain-Bosc M, Roche M, Polge A, et al. Improvement of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. II. Pervasive developmental disorder-autism. Magnes Res. 2006;19:53-62. (Pubitemid 43945611)
132. McGuire JK, Kulkarni MS, Baden HP. Fatal hypermagnesemia in a child treated with megavitamin/megamineral therapy. Pediatrics. 2000;105:E18.
133. Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet. 1998;351:637-641. (Pubitemid 28098447)
134. Lowe TL, Cohen DJ, Miller S, et al. Folic acid and B12 in autism and neuropsychiatric disturbances of childhood. J Am Acad Child Psychiatry. 1981;20:104-111. (Pubitemid 11097137)
135. Gillberg C, Wahlstrom J, Johansson R, et al. Folic acid as an adjunct in the treatment of children with the autism fragile-X syndrome (AFRAX). Dev Med Child Neurol. 1986;28:624-627. (Pubitemid 16031329)
136. Nakano K, Noda N, Tachikawa E, et al. A preliminary study of methylcobalamin therapy in autism. Journal of Tokyo Women's Medical University. 2005;75:64-69.
137. James SJ, Melnyk S, Fuchs G, et al. Efficacy of methylcobalamin and folinic acid treatment on glutathione redox status in children with autism. Am J Clin Nutr. 2009;89:1-6.
138. Moretti P, Peters SU, Del Gaudio D, et al. Brief report: autistic symptoms, developmental regression, mental retardation, epilepsy, and dyskinesias in CNS folate deficiency. J Autism Dev Disord. 2008;38:1170-1177.
139. Moretti P, Sahoo T, Hyland K, et al. Cerebral folate deficiency with developmental delay, autism, and response to folinic acid. Neurology. 2005;64:1088-1090. (Pubitemid 40388474)
140. Ramaekers VT, Blau N, Sequeira JM, et al. Folate receptor autoimmunity and cerebral folate deficiency in low-functioning autism with neurological deficits. Neuropediatrics. 2007;38:276-281. (Pubitemid 351737986)
141. Ramaekers VT, Sequeira JM, Blau N, et al. A milk-free diet downregulates folate receptor autoimmunity in cerebral folate deficiency syndrome. Dev Med Child Neurol. 2008;50:346-352. (Pubitemid 351560294)
142. Niederhofer H. First preliminary results of an observation of Ginkgo Biloba treating patients with autistic disorder. Phytother Res. 2009 Mar 9. [E-pub ahead of print.]
143. Levine J, Aviram A, Holan A, et al. Inositol treatment of autism. J Neural Transm. 1997;104:307-310. (Pubitemid 27196485)
144. Lozoff B, Beard J, Connor J, et al. Long-lasting neural and behavioral effects of iron deficiency in infancy. Nutr Rev. 2006;64:S34-43; discussion S72-91.
145. Halterman JS, Kaczorowski JM, Aligne CA, et al. Iron deficiency and cognitive achievement among school-aged children and adolescents in the United States. Pediatrics. 2001;107:1381-1386. (Pubitemid 32525220)
146. Bruner AB, Joffe A, Duggan AK, et al. Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls. Lancet. 1996;348:992-996. (Pubitemid 26340755)
147. Latif A, Heinz P, Cook R. Iron deficiency in autism and Asperger syndrome. Autism. 2002;6:103-114. (Pubitemid 34187799)
148. Dosman CF, Drmic IE, Brian JA, et al. Ferritin as an indicator of suspected iron deficiency in children with autism spectrum disorder: prevalence of low serum ferritin concentration. Dev Med Child Neurol. 2006;48:1008-1009. (Pubitemid 44768810)
149. Cornish E. A balanced approach towards healthy eating in autism. Journal of Human Nutrition and Dietetics. 1998;11:501-509. (Pubitemid 29192636)
150. Dosman CF, Brian JA, Drmic IE, et al. Children with autism: effect of iron supplementation on sleep and ferritin. Pediatr Neurol. 2007;36:152-158. (Pubitemid 46367520)
151. Sandler RH, Finegold SM, Bolte ER, et al. Short-term benefit from oral vancomycin treatment of regressive-onset autism. J Child Neurol. 2000;15:429-435. (Pubitemid 30460223)
152. Brudnak MA, Rimland B, Kerry RE, et al. Enzyme-based therapy for autism spectrum disorders - is it worth another look? Med Hypotheses. 2002;58:422-428. (Pubitemid 34816284)
153. Brudnak MA. Probiotics as an adjuvant to detoxification protocols. Med Hypotheses. 2002;58:382-385. (Pubitemid 34816276)
154. Blades M. Autism: an interesting dietary case history. Nutrition and Food Science. 2000;30:137-140.
155. Niederhofer H. St John's Wort treating patients with autistic disorder. Phytother Res. 2009;Mar 9[Epub ahead of print].
156. Bolman WM, Richmond JA. A double-blind, placebo-controlled, crossover pilot trial of low dose dimethylglycine in patients with autistic disorder. J
157. Kern JK, Miller VS, Cauller PL, et al. Effectiveness of N,N-dimethylglycine in autism and pervasive developmental disorder. J Child Neurol. 2001;16:169-173. (Pubitemid 32433235)
158. McDougle CJ, Naylor ST, Cohen DJ, et al. Effects of tryptophan depletion in drug-free adults with autistic disorder. Arch Gen Psychiatry. 1996;53:993-1000. (Pubitemid 26384668)
159. Sverd J, Kupietz SS, Winsberg BG, et al. Effects of L-5-hydroxytryptophan in autistic children. J Autism Child Schizophr. 1978;8:171-180. (Pubitemid 10187067)
160. Cannell JJ. Autism and vitamin D. Med Hypotheses. 2008;70:750-759. (Pubitemid 351318090)
161. Stewart C, Latif A. Symptomatic nutritional rickets in a teenager with autistic spectrum disorder. Child Care Health Dev. 2008;34:276-278. (Pubitemid 351228124)
162. Clark JH, Rhoden DK, Turner DS. Symptomatic vitamin A and D deficiencies in an eight-year-old with autism. JPEN J Parenter Enteral Nutr. 1993;17:284-286. (Pubitemid 23136138)
163. Steinemann TL, Christiansen SP. Vitamin A deficiency and xerophthalmia in an autistic child. Arch Ophthalmol. 1998;116:392-393.
164. Uyanik O, Dogangun B, Kayaalp L, et al. Food faddism causing vision loss in an autistic child. Child Care Health Dev. 2006;32:601-602. (Pubitemid 44210099)
165. Megson MN. Is autism a G-alpha protein defect reversible with natural vitamin A? Med Hypotheses. 2000;54:979-983. (Pubitemid 30446940)
166. Shaywitz BA, Siegel NJ, Pearson HA. Megavitamins for minimal brain dysfunction. A potentially dangerous therapy. JAMA. 1977;238:1749-1750.
167. Kimmoun A, Leheup B, Feillet F, et al. [Hypercalcemia revealing iatrogenic hypervitaminosis A in a child with autistic troubles] [In French]. Arch Pediatr. 2008;15:29-32.
168. Jory J, McGinnis WR. Red-cell trace minerals in children with autism. Am J Biochem Biotech. 2008;4:101-104. (Pubitemid 351573644)
169. Pfeiffer CC, Braverman ER. Zinc, the brain and behavior. Biol Psychiatry. 1982;17:513-532. (Pubitemid 12102525)
170. Yorbik O, Olgun A, Kirmizigul P, et al. [Plasma zinc and copper levels in boys with oppositional defiant disorder] [In Turkish]. Turk Psikiyatri Derg. 2004;15:276-281.
171. Jackson MJ, Garrod PJ. Plasma zinc, copper, and amino acid levels in the blood of autistic children. J Autism Child Schizophr. 1978;8:203-208. (Pubitemid 10187070)
172. Yorbik O, Akay C, Sayal A, et al. Zinc status in autistic children. J Trace Elem Exp Med. 2004;17:101-107. (Pubitemid 38533990)
173. Panksepp J. A neurochemical theory of autism. Trends Neurosci. 1979;2:174-177. (Pubitemid 10115864)
174. Vojdani A, Campbell AW, Anyanwu E, et al. Antibodies to neuron-specific antigens in children with autism: possible cross-reaction with encephalitogenic proteins from milk, Chlamydia pneumoniae and Streptococcus group A. J Neuroimmunol. 2002;129:168-177. (Pubitemid 34874922)
175. Vojdani A, Pangborn JB, Vojdani E, et al. Infections, toxic chemicals and dietary peptides binding to lymphocyte receptors and tissue enzymes are major instigators of autoimmunity in autism. Int J Immunopathol Pharmacol. 2003;16:189-199. (Pubitemid 39011223)
176. Vojdani A, O'Bryan T, Green JA, et al. Immune response to dietary proteins, gliadin and cerebellar peptides in children with autism. Nutr Neurosci. 2004;7:151-161. (Pubitemid 39307126)
177. Vojdani A, Bazargan M, Vojdani E, et al. Heat shock protein and gliadin peptide promote development of peptidase antibodies in children with autism and patients with autoimmune disease. Clin Diagn Lab Immunol. 2004;11:515-524. (Pubitemid 38661417)
178. Jyonouchi H, Sun S, Itokazu N. Innate immunity associated with inflammatory responses and cytokine production against common dietary proteins in patients with autism spectrum disorder. Neuropsychobiology. 2002;46:76-84. (Pubitemid 36151308)
179. Ashwood P, Anthony A, Torrente F, et al. Spontaneous mucosal lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms: mucosal immune activation and reduced counter regulatory interleukin-10. J Clin Immunol. 2004;24:664-673. (Pubitemid 40933118)
180. Afzal N, Murch S, Thirrupathy K, et al. Constipation with acquired megarectum in children with autism. Pediatrics. 2003;112:939-942. (Pubitemid 37248705)
181. Barcia G, Posar A, Santucci M, et al. Autism and coeliac disease. J Autism Dev Disord. 2008;38:407-408.
182. Lucarelli S, Frediani T, Zingoni AM, et al. Food allergy and infantile autism. Panminerva Med. 1995;37:137-141.
183. Evangeliou A, Vlachonikolis I, Mihailidou H, et al. Application of a ketogenic diet in children with autistic behavior: pilot study. J Child Neurol. 2003;18:113-118. (Pubitemid 36432339)
184. O'Banion D, Armstrong B, Cummings RA, et al. Disruptive behavior: a dietary approach. J Autism Child Schizophr. 1978;8:325-337. (Pubitemid 10133270)
185. Sponheim E. [Gluten-free diet in infantile autism. A therapeutic trial] [In Norwegian]. Tidsskr Nor Laegeforen. 1991;111:704-707.
186. Reichelt KL, Ekrem J, Scott H. Gluten, milk proteins and autism: dietary intervention effects on behavior and peptide secretion. J Appl Nutr. 1990;42:1-11.
187. Knivsberg AM, Wiig K, Lind G, et al. Dietary intervention in autistic syndromes. Brain Dysfunction. 1990;3:315-327.
188. Knivsberg AM, Reichelt KL, Nodland M, et al. Autistic symptoms and diet: a follow-up study. Scand J Ed Research. 1995;39:223-236.
189. Whiteley P, Rodgers J, Savery D, et al. A gluten-free diet as an intervention for autism and associated spectrum disorders: preliminary findings. Autism. 1999;3:45.
190. Cade R, Privette M, Fregly M, et al. Autism and schizophrenia: intestinal disorders. Nutritional Neuroscience. 2000;3:57-72.
191. Christison GW, Ivany K. Elimination diets in autism spectrum disorders: any wheat amidst the chaff? J Dev Behav Pediatr. 2006;27:S162-S171. (Pubitemid 44620298)
192. Goin-Kochel RP, Mackintosh VH, Myers BJ. Parental reports on the efficacy of treatments and therapies for their children with autism spectrum disorders. Research in Autism Spectrum Disorders. 2009;3:528-537.
193. Knivsberg AM, Reichelt KL, Hoien T, et al. A randomised, controlled study of dietary intervention in autistic syndromes. Nutr Neurosci. 2002;5:251-261. (Pubitemid 34823462)
194. Elder JH, Shankar M, Shuster J, et al. The gluten-free, casein-free diet in autism: results of a preliminary double blind clinical trial. J Autism Dev Disord. 2006;36:413-420. (Pubitemid 43828665)
195. Millward C, Ferriter M, Calver S, et al. Gluten- and casein-free diets for autistic spectrum disorder. Cochrane Database Syst Rev. 2008;(2):CD003498.
196. Adams SJ, Burton N, Cutress A, et al. Development of double blind gluten and casein free test foods for use in an autism dietary trial. J Hum Nutr Diet. 2008;21:374.
197. Arnold GL, Hyman SL, Mooney RA, et al. Plasma amino acids profiles in children with autism: potential risk of nutritional deficiencies. J Autism Dev Disord. 2003;33:449-454. (Pubitemid 37127941)
198. Hediger ML, England LJ, Molloy CA, et al. Reduced bone cortical thickness in boys with autism or autism spectrum disorder. J Autism Dev Disord. 2008;38:848-856. (Pubitemid 351601312)
199. Perry EK, Lee ML, Martin-Ruiz CM, et al. Cholinergic activity in autism: abnormalities in the cerebral cortex and basal forebrain. Am J Psychiatry. 2001;158:1058-1066. (Pubitemid 32623109)
200. Chez MG, Aimonovitch M, Buchanan T, et al. Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate. J Child Neurol. 2004;19:165-169. (Pubitemid 38559707)
201. Hardan AY, Handen BL. A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol. 2002;12:237-241. (Pubitemid 35191350)
202. Chez MG, Nowinski CV, Buchanan CP. Donepezil use in children with autistic spectrum disorders. Ann Neurol. 2000;48:541.
203. Chez MG, Buchanan TM, Becker M, et al. Donepezil hydrochloride: a double-blind study in autistic children. J Pediatr Neurol. 2003;1:83-88.
204. Hertzman M. Galantamine in the treatment of adult autism: a report of three clinical cases. Int J Psychiatry Med. 2003;33:395-398. (Pubitemid 38580416)
205. Nicolson R, Craven-Thuss B, Smith J. A prospective, open-label trial of galantamine in autistic disorder. J Child Adolesc Psychopharmacol. 2006;16:621-629. (Pubitemid 44737215)
206. Niederhofer H, Staffen W, Mair A. Galantamine may be effective in treating autistic disorder. BMJ. 2002;325:1422.
207. Campbell M, Anderson LT, Small AM, et al. Naltrexone in autistic children: a double-blind and placebo-controlled study. Psychopharmacol Bull. 1990;26:130-135. (Pubitemid 20322260)
208. Leboyer M, Bouvard MP, Launay JM, et al. Brief report: a double-blind study of naltrexone in infantile autism. J Autism Dev Disord. 1992;22:309-319.
209. Willemsen-Swinkels SH, Buitelaar JK, Weijnen FG, et al. Placebo-controlled acute dosage naltrexone study in young autistic children. Psychiatry Res. 1995;58:203-215.
210. Bouvard MP, Leboyer M, Launay JM, et al. Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study. Psychiatry Res. 1995;58:191-201.
211. Kolmen BK, Feldman HM, Handen BL, et al. Naltrexone in young autistic children: a double-blind, placebo-controlled crossover study. J Am Acad Child Adolesc Psychiatry. 1995;34:223-231.
212. Willemsen-Swinkels SH, Buitelaar JK, van Engeland H. The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study. Biol Psychiatry. 1996;39:1023-1031. (Pubitemid 26191350)
213. Elchaar GM, Maisch NM, Augusto LM, et al. Efficacy and safety of naltrexone use in pediatric patients with autistic disorder. Ann Pharmacother. 2006;40:1086-1095. (Pubitemid 43886966)
214. Koshes RJ, Rock NL. Use of clonidine for behavioral control in an adult patient with autism. Am J Psychiatry. 1994;151:1714. (Pubitemid 24337609)
215. Ming X, Gordon E, Kang N, et al. Use of clonidine in children with autism spectrum disorders. Brain Dev. 2008;30:454-460.
216. Fankhauser MP, Karumanchi VC, German ML, et al. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry. 1992;53:77-82.
217. Jaselskis CA, Cook EH Jr, Fletcher KE, et al. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol. 1992;12:322-327.
218. Posey DJ, Puntney JI, Sasher TM, et al. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol. 2004;14:233-241. (Pubitemid 38988789)
219. Scahill L, Aman MG, McDougle CJ, et al. A prospective open trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2006;16:589-598. (Pubitemid 44737213)
220. Handen BL, Sahl R, Hardan AY. Guanfacine in children with autism and/or intellectual disabilities. J Dev Behav Pediatr. 2008;29:303-308.
221. Boellner SW, Pennick M, Fiske K, et al. Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder. Pharmacotherapy. 2007;27:1253-1262. (Pubitemid 47339123)
222. Rossignol DA. Hyperbaric oxygen therapy might improve certain pathophysiological findings in autism. Med Hypotheses. 2007;68:1208-1227. (Pubitemid 46498438)
223. Rossignol DA, Rossignol LW. Hyperbaric oxygen therapy may improve symptoms in autistic children. Med Hypotheses. 2006;67:216-228.
224. Rossignol DA, Rossignol LW, James SJ, et al. The effects of hyperbaric oxygen therapy on oxidative stress, inflammation, and symptoms in children with autism: an open-label pilot study. BMC Pediatr. 2007;7:36.
225. Chungpaibulpatana J, Sumpatanarax T, Thadakul N, et al. Hyperbaric oxygen therapy in Thai autistic children. J Med Assoc Thai. 2008;91:1232-1238.
226. Rossignol DA, Rossignol LW, Smith S, et al. Hyperbaric treatment for children with autism: a multicenter, randomized, double-blind, controlled trial. BMC Pediatr. 2009;9:21.
227. Shenoy S, Arnold S, Chatila T. Response to steroid therapy in autism secondary to autoimmune lymphoproliferative syndrome. J Pediatr. 2000;136:682-687. (Pubitemid 30318402)
228. Stefanatos GA, Grover W, Geller E. Case study: corticosteroid treatment of language regression in pervasive developmental disorder. J Am Acad Child Adolesc Psychiatry. 1995;34:1107-1111.
229. Chez MG, Loeffel M, Buchanan C, et al. Pulse high dose steroids as combination therapy with valproic acid in epileptic aphasia patients with pervasive developmental delay or autism. Ann Neurol. 1998;44:539.
230. Buitelaar JK, van Engeland H, de Kogel K, et al. The adrenocorticotrophic hormone (4-9) analog ORG 2766 benefits autistic children: report on a second controlled clinical trial. J Am Acad Child Adolesc Psychiatry. 1992;31:1149-1156.
231. Buitelaar JK, van Engeland H, de Kogel KH, et al. The use of adrenocorticotrophic hormone (4-9) analog ORG 2766 in autistic children: effects on the organization of behavior. Biol Psychiatry. 1992;31:1119-1129.
232. Buitelaar JK, van Engeland H, van Ree JM, et al. Behavioral effects of Org 2766, a synthetic analog of the adrenocorticotrophic hormone (4-9), in 14 outpatient autistic children. J Autism Dev Disord. 1990;20:467-478.
233. Boris M, Kaiser CC, Goldblatt A, et al. Effect of pioglitazone treatment on behavioral symptoms in autistic children. J Neuroinflammation. 2007;4:3.
234. Bradstreet JJ, Smith S, Granpeesheh D, et al. Spironolactone might be a desirable immunologic and hormonal intervention in autism spectrum disorders. Med Hypotheses. 2007;68:979-987. (Pubitemid 46290607)
235. Gupta S, Rimland B, Shilling PD. Pentoxifylline: brief review and rationale for its possible use in the treatment of autism. J Child Neurol. 1996;11:501-504.
236. Heuer L, Ashwood P, Schauer J, et al. Reduced levels of immunoglobulin in children with autism correlates with behavioral symptoms. Autism Res. 2008;1:275-283.
237. Gupta S, Aggarwal S, Heads C. Dysregulated immune system in children with autism: beneficial effects of intravenous immune globulin on autistic characteristics. J Autism Dev Disord. 1996;26:439-452.
238. Plioplys AV. Intravenous immunoglobulin treatment of children with autism. J Child Neurol. 1998;13:79-82. (Pubitemid 28155115)
239. Gupta S. Immunological treatments for autism. J Autism Dev Disord. 2000;30:475-479.
240. DelGiudice-Asch G, Simon L, Schmeidler J, et al. Brief report: a pilot open clinical trial of intravenous immunoglobulin in childhood autism. J Autism Dev Disord. 1999;29:157-160. (Pubitemid 29275101)
241. Plioplys AV. Intravenous immunoglobulin treatment in autism. J Autism Dev Disord. 2000;30:73-74.
242. Boris M, Goldblatt A, Edelson SM. Improvement in children with autism treated with intravenous gamma globulin. J Nutritional Environmental Medicine. 2005;15:169-176. (Pubitemid 44049798)
243. Schneider CK, Melmed RD, Barstow LE, et al. Oral human immunoglobulin for children with autism and gastrointestinal dysfunction: a prospective, open-label study. J Autism Dev Disord. 2006;36:1053-1064. (Pubitemid 46020358)
244. Handen BL, Melmed RD, Hansen RL, et al. A double-blind, placebo-controlled trial of oral human immunoglobulin for gastrointestinal dysfunction in children with autistic disorder. J Autism Dev Disord. 2009;39:796-805.
245. Stubbs EG, Budden SS, Burger DR, et al. Transfer factor immunotherapy of an autistic child with congenital cytomegalovirus. J Autism Dev Disord. 1980;10:451-458. (Pubitemid 11170308)
246. Fudenberg HH. Dialysable lymphocyte extract (DLyE) in infantile onset autism: a pilot study. Biotherapy. 1996;9:143-147. (Pubitemid 26421208)
247. Bartz JA, Hollander E. Oxytocin and experimental therapeutics in autism spectrum disorders. Prog Brain Res. 2008;170:451-462. (Pubitemid 352010247)
248. Lerer E, Levi S, Salomon S, et al. Association between the oxytocin receptor (OXTR) gene and autism: relationship to Vineland Adaptive Behavior Scales and cognition. Mol Psychiatry. 2008;13:980-988.
249. Wu S, Jia M, Ruan Y, et al. Positive association of the oxytocin receptor gene (OXTR) with autism in the Chinese Han population. Biol Psychiatry. 2005;58:74-77. (Pubitemid 40909939)
250. Jacob S, Brune CW, Carter CS, et al. Association of the oxytocin receptor gene (OXTR) in Caucasian children and adolescents with autism. Neurosci Lett. 2007;417:6-9. (Pubitemid 46517832)
251. Modahl C, Green L, Fein D, et al. Plasma oxytocin levels in autistic children. Biol Psychiatry. 1998;43:270-277. (Pubitemid 28085673)
252. Domes G, Heinrichs M, Michel A, et al. Oxytocin improves "mind-reading" in humans. Biol Psychiatry. 2007;61:731-733.
253. Hollander E, Novotny S, Hanratty M, et al. Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders. Neuropsychopharmacology. 2003;28:193-198.
254. Hollander E, Bartz J, Chaplin W, et al. Oxytocin increases retention of social cognition in autism. Biol Psychiatry. 2007;61:498-503. (Pubitemid 46185336)
255. Cohen DJ, Johnson WT, Caparulo BK. Pica and elevated blood lead level in autistic and atypical children. Am J Dis Child. 1976;130:47-48.
256. Accardo P, Whitman B, Caul J, et al. Autism and plumbism. A possible association. Clin Pediatr (Phila). 1988;27:41-44.
257. Eppright TD, Sanfacon JA, Horwitz EA. Attention deficit hyperactivity disorder, infantile autism, and elevated blood-lead: a possible relationship. Mo Med. 1996;93:136-138.
258. Lidsky TI, Schneider JS. Autism and autistic symptoms associated with childhood lead poisoning. Journal of Applied Research. 2005;5:80-87.
259. Kidd PM. Autism, an extreme challenge to integrative medicine. Part II: medical management. Alternative Medicine Review. 2002;7:472-499. (Pubitemid 36025873)
260. Lonsdale D, Shamberger RJ, Audhya T. Treatment of autism spectrum children with thiamine tetrahydrofurfuryl disulfide: a pilot study. Neuro Endocrinol Lett. 2002;23:303-308. (Pubitemid 34987498)
261. Geier DA, Geier MR. A clinical trial of combined anti-androgen and anti-heavy metal therapy in autistic disorders. Neuro Endocrinol Lett. 2006;27:833-838. (Pubitemid 46138649)
262. Patel K, Curtis LT. A comprehensive approach to treating autism and attention-deficit hyperactivity disorder: a prepilot study. J Altern Complement Med. 2007;13:1091-1097.
263. Nataf R, Skorupka C, Amet L, et al. Porphyrinuria in childhood autistic disorder: implications for environmental toxicity. Toxicol Appl Pharmacol. 2006;214:99-108.
264. Bradstreet JJ, Geier DA, Kartzinel JJ, et al. A case-control study of mercury burden in children with autistic spectrum disorders. Journal of American Physicians and Surgeons. 2003;8:76-79.
265. Soden SE, Lowry JA, Garrison CB, et al. 24-hour provoked urine excretion test for heavy metals in children with autism and typically developing controls, a pilot study. Clin Toxicol (Phila). 2007;45:476-481. (Pubitemid 46763682)
266. Shannon M, Graef JW. Lead intoxication in children with pervasive developmental disorders. J Toxicol Clin Toxicol. 1996;34:177-181. (Pubitemid 26112150)
267. Geier DA, Geier MR. A prospective assessment of porphyrins in autistic disorders: a potential marker for heavy metal exposure. Neurotox Res. 2006;10:57-64.
268. Geier DA, Geier MR. A prospective study of mercury toxicity biomarkers in autistic spectrum disorders. J Toxicol Environ Health A. 2007;70:1723-1730. (Pubitemid 47450885)
269. Van der Linde AA, Pillen S, Gerrits GP, et al. Stevens-Johnson syndrome in a child with chronic mercury exposure and 2,3-dimercaptopropane-1-sulfonate (DMPS) therapy. Clin Toxicol (Phila). 2008;46:479-481. (Pubitemid 351878655)
270. Brown MJ, Willis T, Omalu B, et al. Deaths resulting from hypocalcemia after administration of edetate disodium: 2003-2005. Pediatrics. 2006;118:e534-536. (Pubitemid 46085393)
271. Chen ZK, Lu ZQ. Sodium dimercaptopropane sulfonate as antidote against non-metallic pesticides. Acta Pharmacol Sin. 2004;25:534-544.
272. Flora SJ, Pande M, Mehta A. Beneficial effect of combined administration of some naturally occurring antioxidants (vitamins) and thiol chelators in the treatment of chronic lead intoxication. Chem Biol Interact. 2003;145:267-280. (Pubitemid 36549111)
273. Flora SJ, Flora G, Saxena G, et al. Arsenic and lead induced free radical generation and their reversibility following chelation. Cell Mol Biol (Noisy-le-grand). 2007;53:26-47. (Pubitemid 46799689)
274. Rogan WJ, Dietrich KN, Ware JH, et al. The effect of chelation therapy with succimer on neuropsychological development in children exposed to lead. N Engl J Med. 2001;344:1421-1426. (Pubitemid 32402098)
275. Dietrich KN, Ware JH, Salganik M, et al. Effect of chelation therapy on the neuropsychological and behavioral development of lead-exposed children after school entry. Pediatrics. 2004;114:19-26. (Pubitemid 38857561)
276. Bhattacharya A, Shukla R, Auyang ED, et al. Effect of succimer chelation therapy on postural balance and gait outcomes in children with early exposure to environmental lead. Neurotoxicology. 2007;28:686-695. (Pubitemid 46843249)
277. Mitka M. Chelation therapy trials halted. JAMA. 2008;300:2236.
278. Gudarzi SS, Yasamy M, Akhondzadeh S. Cyproheptadine in treatment of autism. Eur Psychiatry. 2002;17:230-231. (Pubitemid 34987827)
279. Akhondzadeh S, Erfani S, Mohammadi MR, et al. Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial. J Clin Pharm Ther. 2004;29:145-150. (Pubitemid 38482479)
280. Linday LA. Oral famotidine: a potential treatment for children with autism. Med Hypotheses. 1997;48:381-386. (Pubitemid 27245023)
281. Linday LA, Tsiouris JA, Cohen IL, et al. Famotidine treatment of children with autistic spectrum disorders: pilot research using single subject research design. J Neural Transm. 2001;108:593-611. (Pubitemid 32441874)
282. Purcell AE, Jeon OH, Zimmerman AW, et al. Postmortem brain abnormalities of the glutamate neurotransmitter system in autism. Neurology. 2001;57:1618-1628. (Pubitemid 33055480)
283. Moreno-Fuenmayor H, Borjas L, Arrieta A, et al. Plasma excitatory amino acids in autism. Invest Clin. 1996;37:113-128.
284. Erickson CA, Chambers JE. Memantine for disruptive behavior in autistic disorder. J Clin Psychiatry. 2006;67:1000. (Pubitemid 44049107)
285. Erickson CA, Posey DJ, Stigler KA, et al. A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl). 2007;191:141-147. (Pubitemid 46294942)
286. Owley T, Salt J, Guter S, et al. A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2006;16:517-524. (Pubitemid 44737207)
287. Chez MG, Burton Q, Dowling T, et al. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J Child Neurol. 2007;22:574-579. (Pubitemid 46951501)
288. Uldall P, Hansen FJ, Tonnby B. Lamotrigine in Rett syndrome. Neuropediatrics. 1993;24:339-340. (Pubitemid 24009798)
289. Mendhekar DN, Duggal HS. Acquired variant of Rett's disorder and response to lamotrigine. J Neuropsychiatry Clin Neurosci. 2007;19:474-475. (Pubitemid 350156113)
290. Kumandas S, Caksen H, Ciftci A, et al. Lamotrigine in two cases of Rett syndrome. Brain Dev. 2001;23:240-242. (Pubitemid 32455529)
291. Stenbom Y, Tonnby B, Hagberg B. Lamotrigine in Rett syndrome: treatment experience from a pilot study. Eur Child Adolesc Psychiatry. 1998;7:49-52. (Pubitemid 28183820)
292. Uvebrant P, Bauziene R. Intractable epilepsy in children. The efficacy of lamotrigine treatment, including non-seizure-related benefits. Neuropediatrics. 1994;25:284-289.
293. Belsito KM, Law PA, Kirk KS, et al. Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord. 2001;31:175-181. (Pubitemid 37490163)
294. Posey DJ, Kem DL, Swiezy NB, et al. A pilot study of D-cycloserine in subjects with autistic disorder. Am J Psychiatry. 2004;161:2115-2117. (Pubitemid 39441414)
295. Sturmey P. Secretin is an ineffective treatment for pervasive developmental disabilities: a review of 15 double-blind randomized controlled trials. Res Dev Disabil. 2005;26:87-97. (Pubitemid 39601466)
296. Esch BE, Carr JE. Secretin as a treatment for autism: a review of the evidence. J Autism Dev Disord. 2004;34:543-556. (Pubitemid 40941081)
297. Williams KW, Wray JJ, Wheeler DM. Intravenous secretin for autism spectrum disorder. Cochrane Database Syst Rev. 2005;(3):CD003495.
298. Ratliff-Schaub K, Carey T, Reeves GD, et al. Randomized controlled trial of transdermal secretin on behavior of children with autism. Autism. 2005;9:256-265. (Pubitemid 40946287)
299. Boso M, Emanuele E, Minazzi V, et al. Effect of long-term interactive music therapy on behavior profile and musical skills in young adults with severe autism. J Altern Complement Med. 2007;13:709-712. (Pubitemid 47585337)
300. Kern P, Aldridge D. Using embedded music therapy interventions to support outdoor play of young children with autism in an inclusive community-based child care program. J Music Ther. 2006;43:270-294.
301. Kim J, Wigram T, Gold C. The effects of improvisational music therapy on joint attention behaviors in autistic children: a randomized controlled study. J Autism Dev Disord. 2008;38:1758-1766.
302. Corbett BA, Shickman K, Ferrer E. Brief report: the effects of Tomatis sound therapy on language in children with autism. J Autism Dev Disord. 2008;38:562-566. (Pubitemid 351322367)
303. Whipple J. Music in intervention for children and adolescents with autism: a meta-analysis. J Music Ther. 2004;41:90-106. (Pubitemid 39202986)
304. Gold C, Wigram T, Elefant C. Music therapy for autistic spectrum disorder. Cochrane Database Syst Rev. 2006;(2):CD004381.
305. Kaplan M, Carmody DP, Gaydos A. Postural orientation modifications in autism in response to ambient lenses. Child Psychiatry Hum Dev. 1996;27:81-91. (Pubitemid 26362294)
306. Kaplan M, Edelson SM, Seip JA. Behavioral changes in autistic individuals as a result of wearing ambient transitional prism lenses. Child Psychiatry Hum Dev. 1998;29:65-76. (Pubitemid 28391703)
307. Chen WX, Wu-Li L, Wong VC. Electroacupuncture for children with autism spectrum disorder: pilot study of 2 cases. J Altern Complement Med. 2008;14:1057-1065.
308. Allam H, ElDine NG, Helmy G. Scalp acupuncture effect on language development in children with autism: a pilot study. J Altern Complement Med. 2008;14:109-114. (Pubitemid 351364399)
309. Rimland B, Edelson SM. Brief report: a pilot study of auditory integration training in autism. J Autism Dev Disord. 1995;25:61-70.
310. Sinha Y, Silove N, Wheeler D, et al. Auditory integration training and other sound therapies for autism spectrum disorders: a systematic review. Arch Dis Child. 2006;91:1018-1022. (Pubitemid 44863143)
311. Cullen-Powell LA, Barlow JH, Cushway D. Exploring a massage intervention for parents and their children with autism: the implications for bonding and attachment. J Child Health Care. 2005;9:245-255.
312. Williams TI. Evaluating effects of aromatherapy massage on sleep in children with autism: a pilot study. Evid Based Complement Alternat Med. 2006;3:373-377. (Pubitemid 44310281)
313. Escalona A, Field T, Singer-Strunck R, et al. Brief report: improvements in the behavior of children with autism following massage therapy. J Autism Dev Disord. 2001;31:513-516. (Pubitemid 37486687)
314. Silva LM, Cignolini A. A medical qigong methodology for early intervention in autism spectrum disorder: a case series. Am J Chin Med. 2005;33:315-327. (Pubitemid 40668106)
315. Silva LM, Ayres R, Schalock M. Outcomes of a pilot training program in a qigong massage intervention for young children with autism. Am J Occup Ther. 2008;62:538-546.
316. Silva LM, Cignolini A, Warren R, et al. Improvement in sensory impairment and social interaction in young children with autism following treatment with an original Qigong massage methodology. Am J Chin Med. 2007;35:393-406. (Pubitemid 47018587)
317. Jarusiewicz B. Efficacy of neurofeedback for children in the autism spectrum: a pilot study. J Neurotherapy. 2002;6:39-49. (Pubitemid 36416628)
318. Robinson TW. Homeopathic secretin in autism: a clinical pilot study. British Homeopathic Journal. 2001;90:86-91.
319. Warwick TC, Griffith J, Reyes B, et al. Effects of vagus nerve stimulation in a patient with temporal lobe epilepsy and Asperger syndrome: case report and review of the literature. Epilepsy Behav. 2007;10:344-347. (Pubitemid 46432235)
320. Park YD. The effects of vagus nerve stimulation therapy on patients with intractable seizures and either Landau-Kleffner syndrome or autism. Epilepsy Behav. 2003;4:286-290. (Pubitemid 37184604)
321. Danielsson S, Viggedal G, Gillberg C, et al. Lack of effects of vagus nerve stimulation on drug-resistant epilepsy in eight pediatric patients with autism spectrum disorders: a prospective 2-year follow-up study. Epilepsy Behav. 2008;12:298-304.